Pier Vincenzo Piazza

Pier Vincenzo Piazza

Auto-generated profile, based on publicly available information

Pier Vincenzo Piazza

Aelis Farma, Bordeaux, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MHMargaret Haney
Margaret Haney
MVMonique Vallée
Monique Vallée
SFSandy Fabre
Sandy Fabre
SRStephanie Collins Reed
Stephanie Collins Reed
MZMarion Zanese
Marion Zanese
PPPier Vincenzo Piazza
Pier Vincenzo Piazza
Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and non-human primates, AEF0117 decreased cannabinoid self-administration and THC-related behavioral impairment without producing significant adverse effects. In single-ascending-dose (0.2 mg, 0.6 mg, 2 mg and 6 mg; n = 40) and multiple-ascending-dose (0.6 mg, 2 mg and 6 mg; n = 24) phase 1 trials, healthy volunteers were randomized to ascending-dose cohorts (n = 8 per cohort; 6:2 AEF0117 to placebo randomization). In both studies, AEF0117 was safe and well tolerated (primary outcome measurements). In a double-blind, placebo-controlled, crossover phase 2a trial, volunteers with CUD were randomized to two ascending-dose cohorts (0.06 mg, n = 14; 1 mg, n = 15). AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.ClinicalTrials.gov identifiers: NCT03325595, NCT03443895 and NCT03717272.

30 September 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
ISIlaria Sciamanna
Ilaria Sciamanna
AGAlberto Gualtieri
Alberto Gualtieri
PPPier Vincenzo Piazza
Pier Vincenzo Piazza
CSCorrado Spadafora
Corrado Spadafora
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ilaria Sciamanna 1 , Alberto Gualtieri 1 , Pier Vincenzo Piazza 2 , Corrado Spadafora 1 1 Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy 2 NeuroCentre Magendie, INSERM U862, Univ Bdx2, Bordeaux, France Correspondence to: Corrado Spadafora, e-mail: cspadaf@tin.it Keywords: Retrotransposon, reverse transcriptase, inhibitor, non coding RNA, cancer therapy Received: August 01, 2014 Accepted: September 16, 2014 Published: October 29, 2014 ABSTRACT LINE-1 retrotransposons encode the reverse transcriptase (RT) enzyme, required for their own mobility, the expression of which is inhibited in differentiated tissues while being active in tumors. Experimental evidence indicate that the inhibition of LINE-1-derived RT restores differentiation in cancer cells, inhibits tumor progression and yields globally reprogrammed transcription profiles. Newly emerging data suggest that LINE-1-encoded RT modulates the biogenesis of miRNAs, by governing the balance between the production of regulatory double-stranded RNAs and RNA:DNA hybrid molecules, with a direct impact on global gene expression. Abnormally high RT activity unbalances the transcriptome in cancer cells, while RT inhibition restores ‘normal’ miRNA profiles and their regulatory networks. This RT-dependent mechanism can target the myriad of transcripts - both coding and non-coding, sense and antisense - in eukaryotic transcriptomes, with a profound impact on cell fates. LINE-1-encoded RT emerges therefore as a key regulator of a previously unrecognized mechanism in tumorigenesis